Press Releases
Back to Previous Page
 


News Release
May 29, 2018
Your Contact:
Karen Tiano +1 978 495 0093

MilliporeSigma Announces Collaboration with Solvias for New Pyrogen Detection Kit
  • Only cell-line-based Monocyte Activation Test (MAT) kit on the market
  • Detects broad spectrum of pyrogens and offers high reproducibility, sensitivity
  • Eliminates the need for live animal testing

Burlington, Massachusetts, May 29, 2018 — MilliporeSigma today announced a collaboration with Solvias, a Swiss contract research and service provider, to offer the PyroMAT™ System, a new MAT kit for pyrogen detection. The kit, which joins other products in MilliporeSigma’s Pyrogen Detection portfolio, was developed collaboratively by the companies.

Because pyrogen contaminations in pharmaceutical products, biotherapeutics and medical devices can induce life-threatening fevers, manufacturers must ensure that pyrogen concentrations do not exceed certain limits. The new PyroMAT™ System, the only cell-line-based MAT kit on the market, detects the full range of pyrogens in pharmaceutical raw materials and products.

“Our new PyroMAT™ System has many advantages over existing methods, which are often limited in the products and range of pyrogens that can be detected,” said Jean-Charles Wirth, Head of Applied Solutions at MilliporeSigma. “This system offers a high-quality, ready-to-use in vitro method that does not require live animal testing and detects the broad spectrum of pyrogens.”

The new kit eliminates the laboratory work required to maintain the cell line, and the cells are qualified in terms of performance and shipment.

“We are pleased that our collaboration with MilliporeSigma to distribute the cell-based test is now coming to fruition,” said Karen Huebscher, CEO, Solvias. “The new PyroMAT™ System has significant potential through distinct advantages over current methods of testing for pyrogens. It produces results that are both reliable and reproducible, characteristics that are essential for quality assurance.”

Follow MilliporeSigma on Twitter @MilliporeSigma, on Facebook @MilliporeSigma and on LinkedIn.

About the Life Science Business of Merck KGaA, Darmstadt, Germany

The Life Science business of Merck KGaA, Darmstadt, Germany, which operates as MilliporeSigma in the U.S. and Canada, has some 21,000 employees and 59 manufacturing sites worldwide, with a portfolio of more than 300,000 products focused on scientific discovery, biomanufacturing and testing services. Udit Batra is the global chief executive officer of MilliporeSigma.

Merck KGaA, Darmstadt, Germany completed its $17 billion acquisition of Sigma-Aldrich in November 2015, creating a leader in the $125 billion global life science industry.

Merck KGaA, Darmstadt, Germany, a leading science and technology company, operates across healthcare, life science and performance materials. Around 52,000 employees work to make a positive difference to millions of people’s lives every day by creating more joyful and sustainable ways to live. From advancing gene-editing technologies and discovering unique ways to treat the most challenging diseases to enabling the intelligence of devices – the company is everywhere. In 2018, Merck KGaA, Darmstadt, Germany, generated sales of €14.8 billion in 66 countries.

The company holds the global rights to the name and trademark “Merck” internationally. The only exceptions are the United States and Canada, where the business sectors of Merck KGaA, Darmstadt, Germany operate as EMD Serono in healthcare, MilliporeSigma in life science, and EMD Performance Materials. Since its founding 1668, scientific exploration and responsible entrepreneurship have been key to the company’s technological and scientific advances. To this day, the founding family remains the majority owner of the publicly listed company. For more information about Merck, KGaA, Darmstadt, Germany, visit www.emdgroup.com.